Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone.

Fiche publication


Date publication

août 2020

Journal

Journal of investigative surgery : the official journal of the Academy of Surgical Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas, Pr ORTEGA DEBALLON Pablo, Pr ROHR Serge, Dr ROMAIN Benoit, Dr LAKKIS Zaher, Pr BRIGAND Cécile


Tous les auteurs :
Mesli Y, Holterbach L, Delhorme JB, Lakkis Z, Ortega-Deballon P, Deguelte S, Rohr S, Brigand C, Meyer N, Romain B

Résumé

The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment.

Mots clés

Somatostatin analogues, dehydration, high-output stoma, lanreotide

Référence

J Invest Surg. 2020 Aug 4;:1-5